Isosorbide Mononitrate Tablet, Extended Release
NDC 71610-772
Product Information
Isosorbide Mononitrate is a ANDA-approved product labeled by Aphena Pharma Solutions - Tennessee, Llc. Isosorbide mononitrate is used to prevent chest pain (angina) in patients with a certain heart condition (coronary artery disease). It is supplied as a white tablet, extended release for oral administration. This product entry covers the primary NDC 71610-772 and 4 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
ING176
Code Structure Chart
Product Details
What is NDC 71610-772?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ISOSORBIDE MONONITRATE (UNII: LX1OH63030)
- ISOSORBIDE MONONITRATE (UNII: LX1OH63030) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- HYPROMELLOSE 2208 (100000 MPA.S) (UNII: VM7F0B23ZI)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- HYDROXYPROPYL CELLULOSE (1200000 WAMW) (UNII: U3JF91U133)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 353538 - isosorbide mononitrate 60 MG 24HR Extended Release Oral Tablet
- RxCUI: 353538 - 24 HR isosorbide mononitrate 60 MG Extended Release Oral Tablet
- RxCUI: 353538 - isosorbide mononitrate 60 MG 24 HR Extended Release Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.